That's OK, I'll spell it out for you. It has to do with the fact that they did not make the connection between tumor infiltrating lymphocytes and nonresponders. Inovio could see the limited upside potential as a monotherapy, especially in light of the advancements in immunotherapy drugs. So why not spend it off to family. I'll bet they wish they had a back, the patent that is . Not knowing that they gave away the key to the greatest unmet need in oncology today.
News 
Market Data 
Discover 
AI
